Final Data from Open-Label Extension Studies of Dalfampridine Extended Release Tablets in Multiple Sclerosis

被引：0
|
作者：
Goodman, Andrew [1 ]
Blight, Andrew [2 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[2] Acorda Therapeut Inc, Hawthorne, NY USA
来源：
NEUROLOGY | 2012年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P04128
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Open-Label Extension Studies: Are They Really Research?
    Cho, Mildred K.
    AMERICAN JOURNAL OF BIOETHICS, 2014, 14 (03): : 1 - 2
  • [32] Effectiveness and safety of oxycodone/naloxone controlled release tablets during three 52-week open-label extension studies
    Moline, M.
    Berger, B.
    Dain, B.
    Munera, C.
    Hopp, M.
    Green, I.
    JOURNAL OF PAIN, 2014, 15 (04): : S90 - S90
  • [33] Open-Label Extension Studies: Are They Really Research?
    Cho, Mildred K.
    AMERICAN JOURNAL OF BIOETHICS, 2014, 14 (04): : 60 - 61
  • [34] Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis
    Weir, Scott
    Torkin, Risa
    Henney, Herbert R., III
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (12) : 1627 - 1636
  • [35] Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
    Hayes, Keith C.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 : 229 - 239
  • [36] Hepatic safety of ozanimod in relapsing multiple sclerosis in the DAYBREAK open-label extension study
    Selmaj, K.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Afsari, S.
    Shi, F.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 608 - 609
  • [37] Safety Patterns Over up to 8 Years With Ozanimod in Patients with Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
    Selmaj, Krzysztof
    Ziemssen, Tjalf
    Comi, Giancarlo
    Hartung, Hans-Peter
    Sheffield, James
    Cheng, Chun-Yen
    Riolo, Jon
    Thorpe, Andrew
    Krakovich, Anthony
    Singal, Mohini
    Vermersch, Patrick
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1019 - 1020
  • [38] Open-label extension studies: Interpretation and statistical issues
    Weatherall M.
    Burgess C.
    Taylor W.
    International Journal of Pharmaceutical Medicine, 2007, 21 (2) : 115 - 120
  • [39] Update on Hepatic Safety of Ozanimod in Relapsing Multiple Sclerosis in the DAYBREAK Open-Label Extension Trial
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Hartung, H. P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Thorpe, A.
    Riolo, J. V.
    Krakovich, A.
    Cheng, C. Y.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 325 - 326
  • [40] Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment
    Hersh, Carrie
    Rae-Grant, Alex
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2012, 5 (04) : 199 - 204
12345